Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation

Wong, Darren; Thomas, William; Butler, Andrew; Sharkey, Lisa

doi:10.1136/bcr-2021-241634

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab (an anti-CD20 monoclonal antibody targeting B-lymphocytes) is a second-line treatment for w-AIHA, especially for refractory AIHA ( 34 , 35 ). In pediatric patients, it has been shown that rituximab is effective in treating patients with corticosteroid-resistant AIHA and effective as a second treatment course in patients with relapsing AIHA ( 36 , 37 ).…”

Section: Discussionmentioning

confidence: 99%

Type O blood, the MCHC, and the reticulocyte count impact the early recurrence of primary warm-antibody autoimmune hemolytic anemia in children: A retrospective cohort analysis

et al. 2022

Front. Pediatr.

View full text Add to dashboard Cite

ObjectivePrimary warm-antibody autoimmune hemolytic anemia (w-AIHA) is prone to recurrence in children. In this study, we aimed to identify risk indicators for the early recurrence of primary w-AIHA and construct an effective recurrence risk assessment model.MethodsThis was a retrospective cohort study. The clinical data of patients hospitalized with primary w-AIHA in the Department of Hematology and Oncology, Children's Hospital of Chongqing Medical University, between 1 January 2018 and 30 September 2021, were collected at the initial diagnosis. Univariate and multivariate logistic regression analyses were used to determine risk indicators for the early recurrence of primary w-AIHA in children, and ROC curve and Kaplan–Meier survival analyses were used for verification. Finally, a risk assessment model for early recurrence in children with primary w-AIHA was constructed using Cox regression and visualized using a nomogram. The model was also verified internally and externally.ResultsThis study included 62 children with primary w-AIHA. Of which, 18 experienced recurrence 1 year after the initial diagnosis. The univariate and multivariate logistic regression analyses showed that type O blood and the reticulocyte count (Ret) were risk indicators for the early recurrence of pediatric primary w-AIHA (P = 0.009, 0.047, respectively). The mean corpuscular hemoglobin concentration (MCHC) is a protective factor (P = 0.040). According to the ROC curve and Kaplan–Meier survival analyses, children with primary w-AIHA whose blood type was O or had an MCHC of <313.5 pg/fL or a Ret of ≥0.161×1012/L had a higher risk of early recurrence (HR = 2.640, 4.430 and 4.450, respectively, and P = 0.040, 0.015 and 0.018, respectively). The blood types (O), MCHCs, and Rets of 56 patients were incorporated into the Cox regression model, and the recurrence risk assessment model for children with primary w-AIHA was successfully constructed and visualized using a nomogram. The calibration curves and decision-curve analysis (DCA) suggested that the risk model has clinical applicability and effectiveness.ConclusionChildren with type O blood and an MCHC value of <313.5 pg/fL or a Ret value of ≥0.161×1012/L have a higher risk of early recurrence. The risk assessment model for the early recurrence of pediatric primary w-AIHA constructed in this study has good clinical applicability and effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Type O blood, the MCHC, and the reticulocyte count impact the early recurrence of primary warm-antibody autoimmune hemolytic anemia in children: A retrospective cohort analysis

et al. 2022

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Bortezomib has been reported to be effective in the setting of hematopoietic and solid organ transplant-associated AIHA in a number of case reports [ 162 , 163 , 164 , 165 , 166 , 167 ]. In retrospective case series and case reports on relapsed refractory wAIHA, bortezomib in combination with dexamethasone had an overall response rate of 85%, with five CR (35%) and seven PR (50.0%) [ 168 , 169 , 170 ] ( Table 2 ).…”

Section: Novel Agentsmentioning

confidence: 99%

Development of New Drugs for Autoimmune Hemolytic Anemia

Xiao

Murakhovskaya

2022

Pharmaceutics

View full text Add to dashboard Cite

Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes corticosteroids and rituximab, is associated with adverse effects as well as treatment failures, and relapses are common. Subsequent lines of therapy are associated with higher rates of toxicity, and some patients remain refractory to currently available treatments. Novel therapies have become promising for this vulnerable population. In this review, we will discuss the mechanism of action, existing data, and ongoing clinical trials of current novel therapies for AIHA, including B-cell-directed therapy, phagocytosis inhibition, plasma cell-directed therapy, and complement inhibition.

show abstract

Multiple drugs

2021

Reactions Weekly

View full text Add to dashboard Cite

Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation

Cited by 4 publications

References 21 publications

Type O blood, the MCHC, and the reticulocyte count impact the early recurrence of primary warm-antibody autoimmune hemolytic anemia in children: A retrospective cohort analysis

Type O blood, the MCHC, and the reticulocyte count impact the early recurrence of primary warm-antibody autoimmune hemolytic anemia in children: A retrospective cohort analysis

Development of New Drugs for Autoimmune Hemolytic Anemia

Multiple drugs

Contact Info

Product

Resources

About